Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT01850524 trial: what clinicians have said so far
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
- NCT01850524 ↗
- Completed
- Millennium Pharmaceuticals, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT01850524 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01850524 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib; Placebo; Dexamethasone; Lenalidomide
- Arms
- Placebo + LenDex · Placebo comparator
- Active Comparator: Ixazomib + LenDex · Active comparator
- Enrollment
- 705
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Start
- Apr 29, 2013
- Primary completion
- Dec 2, 2019
- Results posted
- Yes
- Registry record
- NCT01850524 · updated Jul 21, 2023
Publications
linked from the registry- Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021 Jul 1;137(26):3616-3628. doi: 10.1182/blood.2020008787. PubMed 33763699